Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ivaltinostat by CG Invites for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Ivaltinostat is under clinical development by CG Invites and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
Ivaltinostat by CG Invites for Alport Syndrome: Likelihood of Approval
Ivaltinostat is under clinical development by CG Invites and currently in Phase I for Alport Syndrome. According to GlobalData, Phase...
Ivaltinostat by CG Invites for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Ivaltinostat is under clinical development by CG Invites and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure)....
Ivaltinostat by CG Invites for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Ivaltinostat is under clinical development by CG Invites and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...